In particular, in patients with advanced NSCLC, nivolumab, atezolizumab and pembrolizumab have been first approved by the U.S. Food and Drug Administration as single agents in the second-line setting of treatment and then they have been approved in the first-line setting: as single agents in PDL-1 positive patients (pembrolizumab and atezolizumab), in combination with chemotherapy in patients with any histology (pembrolizumab) or non-squamous histology (atezolizumab), or in combination with ipilimumab in PDL-1 positive patients or with ipilimumab and two cycles of chemotherapy (nivolumab). The gene discussed is CD274; the disease is non-small cell lung carcinoma.